Nitazoxanide triple therapy significantly improves H. pylori cure rates compared to standard treatment

Many people struggle with Helicobacter pylori infections because standard treatments often fail to clear the bacteria. A new analysis looked at whether adding a drug called nitazoxanide to the usual three-drug mix could change that outcome. The researchers combined data from multiple studies involving 1286 participants to get a clearer picture. They compared this nitazoxanide-based triple therapy against standard triple therapy. The results showed a significant improvement in how often the infection was successfully cleared from the body. This held true whether doctors counted everyone who started the treatment or only those who finished it without stopping early. The improvement was consistent across different ways of measuring success. Patients also reported less abdominal pain and nausea, though these changes were not statistically significant. The certainty of this evidence was consistently high. However, the risk of bias in the included studies ranged from low to high. Future research should focus on the optimal duration of nitazoxanide use, resistance patterns, safety, and symptom relief.